smile.amazon.com

If you’re an Amazon customer, it’s easy to donate to IMBCR automatically, with almost every purchase. Just go to www.smile.amazon.com and follow 2 simple steps. STEP 1: Go to www.smile.amazon.com and enter “Institute for Myeloma & Bone Cancer Research” (NOT imbcr.org) into the “Search for your charity” box. STEP 2: When our name pops up READ MORE

Four Seasons Fundraiser

Luncheon with the Stars Four Seasons Los Angeles – Sunday, October 22nd 300 South Doheny Drive, Los Angeles, CA 90048 11.30 am to 2.30 pm Click For More Fundraiser Info

Exciting, new approaches to myeloma treatment

Exciting, new approaches to myeloma treatment are now being developed and tested in the clinic We have made continued progress both in our discovery of new treatments for myeloma and ways to monitor the disease. Our work in the research laboratory has uncovered a new approach to myeloma that is now being tested in the READ MORE

Anti-angiogenic and anti-multiple myeloma effects of oprozomib (OPZ) alone and in combination with pomalidomide (Pom) and/or dexamethasone (Dex)

Sanchez E, Li M, Wang CS, Tang G, Gillespie A, Chen H, Berenson JR Abstract Oprozomib (OPZ or ONYX 0912) is an irreversible, orally administered proteasome inhibitor (PI) and an analog of carfilzomib. We set out to determine the anti-angiogenic effect of OPZ using the choriollantoic membrane/feather bud (CAM/FB) model and its anti-MM effects using READ MORE

Outcomes of Multiple Myeloma Patients Receiving Bortezomib, Lenalidomide and Carfilzomib

Berenson A, Vardanyan S, David M, Wang J, Harutyunyan NM, Gottlieb J, Halleluyan R, Spektor TM, Udd KA Eshaghian S, Nassir Y, Eades B, Swift R, Berenson JR Abstract New classes of drugs including the proteasome inhibitors (PI) bortezomib and, more recently, carfilzomib and the immunomodulatory agent lenalidomide have shown improved outcomes for multiple myeloma READ MORE

Serum B-Cell Maturation Antigen: A Novel Biomarker to Predict Outcomes for Multiple Myeloma Patients

Michael Ghermezi, Mingjie Li, Suzie Vardanyan, Nika Manik Harutyunyan, Jillian Gottlieb, Ariana Berenson, Tanya M. Spektor, Claudia Andreu-Vieyra, Sophia Petraki, Eric Sanchez, Kyle Udd, Cathy S. Wang, Regina A. Swift, Haiming Chen, James R Berenson Abstract B-cell maturation antigen is expressed on plasma cells. In this study, we have identified serum B-call maturation antigen as READ MORE

TRAF6 Is Over-Expressed in Multiple Myeloma and Blocking Its Intracellular Signaling Shows Both Anti-Tumor and Anti-Bone Resorptive Effects

Chen H, Li M, Sanchez E, Wang CS, Lee T, Soof CM, Casas CE, Cao J, Xie C, Udd KA, DeCorso K, Tang GY, Spektor TM, Berenson JR. Abstract Tumor necrosis factor receptor-associated factor 6 (TRAF6) has been implicated in polyubiquitin-mediated IL-1R/TLR signaling through activation of IκB kinase (IKK) to regulate the NF-κB and JNK READ MORE

A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma.

Berenson J, Manges R, Badarinath S, Cartmell A, McIntyre K, Lyons R, Harb W, Mohamed H, Nourbakhsh A, Rifkin R Abstract Elotuzumab, an immunostimulatory SLAMF7-targeting monoclonal antibody, induces myeloma cell death with minimal effects on normal tissue. In a previous phase 3 study in patients with relapsed/refractory multiple myeloma (RRMM), elotuzumab (10 mg/kg, ∼3-h infusion), READ MORE